抗结核药物性肝损伤的研究进展

被引：18

作者：

刘奉凤

陈耀凯

机构：

[1] 重庆市公共卫生医疗救治中心感染科

来源：

重庆医学 | 2014年 / 43卷 / 19期

关键词：

抗结核药物; 肝损伤; 研究进展;

D O I：

暂无

中图分类号：

R575 [肝及胆疾病];

学科分类号：

摘要：

<正>抗结核药物性肝损伤(anti-tuberculosis drug induced liver injury,ATLI)是抗结核药物最为严重的不良反应,其发生率约占抗结核药物不良反应的7%,常导致停药并进而引起治疗失败、病情复发和耐药发生[1-3]。及时、恰当地处置ATLI可减少其对结核病治疗的不良影响,也能最大限度地减少对患者的伤害。作者就ATLI相关研究进展作一综述。1抗结核药物及其肝毒性

引用

页码：2512 / 2514

页数：3

共 7 条

[1] 护肝药在结核病治疗中的应用价值 [J].

赵丽 .

中国医院用药评价与分析, 2008, (10) :782-783

[2] A Guide to the Management of Tuberculosis in Patients with Chronic Liver Disease [J].

Dhiman, Radha K. ;

Saraswaty, Vivek A. ;

Rajekar, Harshal ;

Reddy, Chandrasekhar ;

Chawla, Yogesh K. .

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2012, 2 (03) :260-270

[3]

Tuberculosis drug development pipeline: progress and hope[J] . Melvin Spigelman,Stephen Gillespie.The Lancet . 2006 (9514)

[4] Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin [J].

Tasduq, SA ;

Peerzada, K ;

Koul, S ;

Bhat, R ;

Johri, RK .

HEPATOLOGY RESEARCH, 2005, 31 (03) :132-135

[5]

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment[J] . M. Sharifzadeh,M. Rasoulinejad,F. Valipour,M. Nouraie,S. Vaziri.Pharmacological Research . 2004 (4)

[6] Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy [J].

Dean, GL ;

Edwards, SG ;

Ives, NJ ;

Matthews, G ;

Fox, EF ;

Navaratne, L ;

Fisher, M ;

Taylor, GP ;

Miller, R ;

Taylor, CB ;

de Ruiter, A ;

Pozniak, AL .

AIDS, 2002, 16 (01) :75-83

[7]

Isoniazid – and rifampicin–induced oxidative hepatic injury – protection by N–acetylcysteine .2 S Attri,S V Rana,K Vaiphei,C P Sodhi,R Katyal,R C Goel,C K Nain,K Singh. Human & Experimental Toxicology . 2000

← 1 →